Literature DB >> 28667006

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.

Apinya Jusakul1,2,3, Ioana Cutcutache4, Chern Han Yong1,4, Jing Quan Lim2,5, Mi Ni Huang4, Nisha Padmanabhan1, Vishwa Nellore6, Sarinya Kongpetch2,7,8, Alvin Wei Tian Ng9, Ley Moy Ng10, Su Pin Choo11, Swe Swe Myint2, Raynoo Thanan12, Sanjanaa Nagarajan2, Weng Khong Lim1,2, Cedric Chuan Young Ng2, Arnoud Boot1,4, Mo Liu1,4, Choon Kiat Ong5, Vikneswari Rajasegaran2, Stefanus Lie2,13, Alvin Soon Tiong Lim14, Tse Hui Lim14, Jing Tan2, Jia Liang Loh2, John R McPherson4, Narong Khuntikeo7,15, Vajaraphongsa Bhudhisawasdi15, Puangrat Yongvanit7, Sopit Wongkham12, Yasushi Totoki16, Hiromi Nakamura16, Yasuhito Arai16, Satoshi Yamasaki17, Pierce Kah-Hoe Chow18, Alexander Yaw Fui Chung19, London Lucien Peng Jin Ooi19, Kiat Hon Lim20, Simona Dima21, Dan G Duda22, Irinel Popescu21, Philippe Broet23, Sen-Yung Hsieh24, Ming-Chin Yu25, Aldo Scarpa26, Jiaming Lai27, Di-Xian Luo28, André Lopes Carvalho29, André Luiz Vettore30, Hyungjin Rhee31, Young Nyun Park31, Ludmil B Alexandrov32, Raluca Gordân33,34, Steven G Rozen35,4,36, Tatsuhiro Shibata37,17, Chawalit Pairojkul38, Bin Tean Teh35,2,10,36,39, Patrick Tan35,10,36,40.   

Abstract

Cholangiocarcinoma (CCA) is a hepatobiliary malignancy exhibiting high incidence in countries with endemic liver-fluke infection. We analyzed 489 CCAs from 10 countries, combining whole-genome (71 cases), targeted/exome, copy-number, gene expression, and DNA methylation information. Integrative clustering defined 4 CCA clusters-fluke-positive CCAs (clusters 1/2) are enriched in ERBB2 amplifications and TP53 mutations; conversely, fluke-negative CCAs (clusters 3/4) exhibit high copy-number alterations and PD-1/PD-L2 expression, or epigenetic mutations (IDH1/2, BAP1) and FGFR/PRKA-related gene rearrangements. Whole-genome analysis highlighted FGFR2 3' untranslated region deletion as a mechanism of FGFR2 upregulation. Integration of noncoding promoter mutations with protein-DNA binding profiles demonstrates pervasive modulation of H3K27me3-associated sites in CCA. Clusters 1 and 4 exhibit distinct DNA hypermethylation patterns targeting either CpG islands or shores-mutation signature and subclonality analysis suggests that these reflect different mutational pathways. Our results exemplify how genetics, epigenetics, and environmental carcinogens can interplay across different geographies to generate distinct molecular subtypes of cancer.Significance: Integrated whole-genome and epigenomic analysis of CCA on an international scale identifies new CCA driver genes, noncoding promoter mutations, and structural variants. CCA molecular landscapes differ radically by etiology, underscoring how distinct cancer subtypes in the same organ may arise through different extrinsic and intrinsic carcinogenic processes. Cancer Discov; 7(10); 1116-35. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28667006      PMCID: PMC5628134          DOI: 10.1158/2159-8290.CD-17-0368

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  74 in total

1.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

2.  High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.

Authors:  Warapen Treekitkarnmongkol; Tuangporn Suthiphongchai
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Recursively partitioned mixture model clustering of DNA methylation data using biologically informed correlation structures.

Authors:  Devin C Koestler; Brock C Christensen; Carmen J Marsit; Karl T Kelsey; E Andres Houseman
Journal:  Stat Appl Genet Mol Biol       Date:  2013-03-05

5.  Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data.

Authors:  Valentina Boeva; Tatiana Popova; Kevin Bleakley; Pierre Chiche; Julie Cappo; Gudrun Schleiermacher; Isabelle Janoueix-Lerosey; Olivier Delattre; Emmanuel Barillot
Journal:  Bioinformatics       Date:  2011-12-06       Impact factor: 6.937

6.  Curated collection of yeast transcription factor DNA binding specificity data reveals novel structural and gene regulatory insights.

Authors:  Raluca Gordân; Kevin F Murphy; Rachel P McCord; Cong Zhu; Anastasia Vedenko; Martha L Bulyk
Journal:  Genome Biol       Date:  2011-12-21       Impact factor: 13.583

7.  Recurrent somatic mutations in regulatory regions of human cancer genomes.

Authors:  Collin Melton; Jason A Reuter; Damek V Spacek; Michael Snyder
Journal:  Nat Genet       Date:  2015-06-08       Impact factor: 38.330

8.  Genome-wide analysis of noncoding regulatory mutations in cancer.

Authors:  Nils Weinhold; Anders Jacobsen; Nikolaus Schultz; Chris Sander; William Lee
Journal:  Nat Genet       Date:  2014-09-28       Impact factor: 38.330

9.  Oncogenic FGFR3 gene fusions in bladder cancer.

Authors:  Sarah V Williams; Carolyn D Hurst; Margaret A Knowles
Journal:  Hum Mol Genet       Date:  2012-11-21       Impact factor: 6.150

10.  Copynumber: Efficient algorithms for single- and multi-track copy number segmentation.

Authors:  Gro Nilsen; Knut Liestøl; Peter Van Loo; Hans Kristian Moen Vollan; Marianne B Eide; Oscar M Rueda; Suet-Feung Chin; Roslin Russell; Lars O Baumbusch; Carlos Caldas; Anne-Lise Børresen-Dale; Ole Christian Lingjaerde
Journal:  BMC Genomics       Date:  2012-11-04       Impact factor: 3.969

View more
  210 in total

1.  Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.

Authors:  Ruidong Xue; Lu Chen; Chong Zhang; Masashi Fujita; Ruoyan Li; Shu-Mei Yan; Choon Kiat Ong; Xiwen Liao; Qiang Gao; Shota Sasagawa; Yanmeng Li; Jincheng Wang; Hua Guo; Qi-Tao Huang; Qian Zhong; Jing Tan; Lisha Qi; Wenchen Gong; Zhixian Hong; Meng Li; Jingmin Zhao; Tao Peng; Yinying Lu; Kiat Hon Tony Lim; Arnoud Boot; Atushi Ono; Kazuaki Chayama; Zemin Zhang; Steve George Rozen; Bin Tean Teh; Xin Wei Wang; Hidewaki Nakagawa; Mu-Sheng Zeng; Fan Bai; Ning Zhang
Journal:  Cancer Cell       Date:  2019-05-23       Impact factor: 31.743

Review 2.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

3.  Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.

Authors:  Huat C Lim; Meagan Montesion; Thomas Botton; Eric A Collisson; Sarah E Umetsu; Spencer C Behr; John D Gordan; Phil J Stephens; Robin K Kelley
Journal:  Oncologist       Date:  2018-04-05

Review 4.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

5.  Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing.

Authors:  Amrendra Mishra; Fatemeh Emamgholi; Zulrahman Erlangga; Björn Hartleben; Kristian Unger; Katharina Wolff; Ulrike Teichmann; Michael Kessel; Norman Woller; Florian Kühnel; Lukas E Dow; Michael P Manns; Arndt Vogel; Scott W Lowe; Anna Saborowski; Michael Saborowski
Journal:  Carcinogenesis       Date:  2020-05-14       Impact factor: 4.944

6.  In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)".

Authors:  Angela Dalia Ricci; Alessandro Rizzo; Giovanni Brandi
Journal:  Oncologist       Date:  2021-02-15

7.  Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma.

Authors:  Ubonrat Thamrongwaranggoon; Sakkarn Sangkhamanon; Wunchana Seubwai; Paksiree Saranaruk; Ubon Cha'on; Sopit Wongkham
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

Review 8.  Precision medicine in cholangiocarcinoma.

Authors:  Antonio Pellino; Fotios Loupakis; Massimiliano Cadamuro; Vincenzo Dadduzio; Matteo Fassan; Maria Guido; Umberto Cillo; Stefano Indraccolo; Luca Fabris
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-12

Review 9.  A review of systemic therapy in biliary tract carcinoma.

Authors:  Holger Jansen; Ulrich-Frank Pape; Nalân Utku
Journal:  J Gastrointest Oncol       Date:  2020-08

Review 10.  The implications of IDH mutations for cancer development and therapy.

Authors:  Christopher J Pirozzi; Hai Yan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.